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S U M M A R Y
Objectives: Leprosy household contacts represent a group at high risk of developing the disease. The aim
of this study was to detect Mycobacterium leprae subclinical infection in this group through serological
and molecular parameters.
Methods: Serum anti-PGL1 IgG/IgM and salivary anti-PGL1 IgA/IgM was investigated using an ELISA, and
nasal carriage of M. leprae DNA was detected by PCR, in leprosy household contacts of paucibacillary (PB)
and multibacillary (MB) household leprosy patients (n = 135), their index cases (n = 30), and in persons
living in a low endemic city (n = 17).
Results: Salivary anti-PGL1 IgA and IgM and serum anti-PGL1 IgG showed good correlation comparing
contacts and index cases (p < 0.01, p < 0.005, and p < 0.0001, respectively). This was not observed for
serum anti-PGL1 IgM (p > 0.05). A high frequency of anti-PGL1 IgM positivity was found in IgG-negative
samples (p < 0.0001). For IgG-positive samples, IgM antibodies were also positive in most of the samples.
None of the 17 volunteers living in a low endemic city presented seropositivity for IgG; however, two of
them showed positivity for anti-PGL1 IgM. M. leprae DNA was found in the nasal swabs of nine out of the
85 MB household leprosy contacts (10.6%) and in three out of the 50 PB household leprosy contacts
(6.0%).
Conclusion: We strongly suggest that serum IgG/IgM and salivary anti-PGL1 IgA/IgM measurements are
used to follow leprosy household contacts.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Leprosy remains a public health challenge, with approximately
250 000 new cases being reported each year worldwide.1 Brazil has
the second highest number of cases in the world, with 33 955 new
cases registered in 2011.2 In 2012, a total of 2066 cases were
reported in the state of Ceara´, which represents a detection
coefﬁcient of 24 cases per 100 000 inhabitants.3
Strategies for leprosy control include the administration of
multidrug therapy to the patients and vaccination of household* Corresponding author. Tel.: +55 85 33668270; fax: +55 85 33668292.
E-mail addresses: tiemindi@yahoo.com.br, paulabbcc@yahoo.com.br
(A.T. Nagao-Dias).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.05.011contacts with the bacille Calmette–Gue´rin (BCG) vaccine.4 The
World Health Organization (WHO) also recommends clinical
evaluation of leprosy household contacts and health education
as part of the disease control strategy.1 Physical examination does
not identify the early stages of the disease, when clinical
manifestations are rarely present.5,6 Therefore, it is necessary to
employ more sensitive tools in order to investigate Mycobacterium
leprae infection among household contacts.5 Serological and PCR
tests have been used in seroepidemiological studies.1,6
Phenolic glycolipid (PGL1) is an M. leprae-speciﬁc antigen,7 and
this dominant lipid in the cell wall is responsible for its
immunological speciﬁcity.8 The most studied antibody isotype is
the serum anti-PGL1 IgM.9–12 Few studies have evaluated salivary
anti-PGL1 IgA and IgM,13,14 or serum anti-PGL1 IgG.7,14–17 Our
previous work suggested that salivary anti-PGL1 IgA and IgMses. Published by Elsevier Ltd. All rights reserved.
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known that individuals seropositive for anti-PGL1 antibodies have
a 7.5-fold greater risk of acquiring leprosy compared to seronega-
tive contacts.18 A prospective study9 demonstrated that two
seropositive contacts progressed to clinical, borderline tuberculoid
(BT) leprosy within 1 year of follow-up.
Several authors have described methods to detect M. leprae
based on nucleic acid ampliﬁcation techniques,6,19–23 since direct
bacterial detection tests have too low sensitivity.24
In the present work, we evaluated serum IgG/IgM and salivary
IgA/IgM against PGL1 in addition to the detection of nasal carriage
of M. leprae in leprosy household contacts and their index cases.
2. Materials and methods
2.1. Patients and contacts
Thirty leprosy patients (median age 45 years) and 135
household contacts (median age 26 years) living in the cities
of Crato and Maracanau´, Ceara´ State, Brazil, were included in the
study. Seventeen individuals living in a city with a low incidence
of leprosy (city of Sao Paulo) who reported no contact with
leprosy patients were also included in the project for serological
evaluation (control group – CT group). In 2012, the detection
rates of leprosy in the cities of Crato and Maracanau´ were 42.8
and 30.5 per 100 000 inhabitants, respectively.3 The detection
rate of leprosy in the city of Sao Paulo was 2.21 per 100 000
inhabitants in 2011.25
Leprosy diagnosis and classiﬁcation of the index cases were
based on clinical assessment and on the detection of acid-fast
bacilli in slit skin smears. The leprosy patients were classiﬁed as
paucibacillary (PB) or multibacillary (MB), according to the lesion
count.26 Seventeen were classiﬁed as MB patients and 13 as PB
patients. Fifty out of 135 (37.0%) were contacts of PB leprosy
patients, and 85 out of 135 (63.0%) were contacts of MB leprosy
patients.
The study was approved by the Ethics Committee of the
Universidade Federal do Ceara´, and each participant or his/her
guardian provided written informed consent.
2.2. Samples
Serum samples were collected and stored at 20 8C. Unstimu-
lated saliva was collected 30 min after water consumption and 2 h
after solid food intake and kept at 20 8C. Using sterile swabs
moistened in 0.9% saline solution, nasal secretions were collected
from both nostrils by gently swabbing the outer nares. Each swab
tip was placed into a tube containing 300 ml of lysis solution and
kept at 20 8C. The lysis solution was comprised of 100 mM Tris–
HCl, pH 8.5, with 3% Triton X-100 and 1 mg/ml proteinase K.
2.3. Serum analysis
Serological analysis for anti-PGL1 antibodies was performed
in accordance with the procedure described by Nagao-Dias
et al.14
Polystyrene microplates (Costar, USA) were coated with
10 mg/l of native PGL1 in absolute ethyl alcohol, kindly
donated by Dr John Spencer, Colorado State University, USA.
The plates were incubated for 18 h at room temperature
(RT). For serum IgG and IgM antibody measurements, the
microplates were incubated with 1% bovine serum albumin
(BSA, Sigma, USA) in phosphate buffered saline (PBS, pH 7.4)
for 2 h at RT. After four washes with PBS–0.01% BSA, serum
samples previously diluted 1:50 in PBS–0.5% BSA were
added to the plates in duplicate. The plates were thenincubated overnight at 4 8C. After washing, peroxidase-
labeled anti-IgG or anti-IgM (Sigma, USA) previously diluted
1:1000 was added to the plates and incubated for 1.5 h at
RT. After washing, the plates were incubated for 30 min
with the substrate solution which contained 0.4 mg ortho-
phenylenediamine per milliliter of 0.01 M citrate–phosphate
buffer, pH 5.0. The reaction was interrupted by adding 25 ml
of 2.5 N sulfuric acid. The analysis was performed at 492 nm
using an ELISA plate reader. An aliquot of pooled normal
human serum was used as cut-off sample and tested in all
assays. The results were expressed according to the
following formula: optical density (OD) mean of the test
sample (minus blank) divided by the OD mean of the
normal human serum pool (minus blank). The cut-off was
considered to be 1.0. Values above 1.3, which were 30%
above the cut-off, were considered to be positive.14
2.4. Salivary analysis
For salivary IgA and IgM measurements, PGL1-coated plates
were blocked with 1% BSA–Tris solution for 2 h at RT. Saliva
samples, previously centrifuged at 2600  g for 15 min at 4 8C,
were diluted 1:50 with 0.5% BSA–Tris, added to the plates, and
incubated for 18 h at 4 8C. After four washes with 0.01% BSA–Tris,
alkaline phosphatase-conjugated anti-IgA or anti-IgM (Sigma,
USA) was diluted 1:1000 in 0.5% BSA–Tris and added to the plates.
The plates were then incubated for 2 h at RT. After washing, the
plates were incubated with the substrate solution (1 mg/ml p-
nitrophenyl phosphate in 10% diethanolamine containing 0.5 mM
MgCl2, pH 9.8). After 100 min, absorbance readings were recorded
at 405 nm using an ELISA plate reader. The results were expressed
as the OD mean of the values (minus blank). The cut-off was
considered to be the 97th percentile of normal controls.14 Results
considered to be 30% above the cut-off value were considered to be
positive. Blank samples contained all reagents except for saliva or
serum.
2.5. Molecular M. leprae detection
Detection of M. leprae DNA in nasal swabs was performed in
accordance with the procedures described by Torres et al.21 and De
Wit et al.,27 with some modiﬁcations.
The nasal swabs immersed in lysis buffer were incubated at
55 8C for 18 h followed by incubation for 15 min at 97 8C. After
removing the swabs, 135 ml of 5 M NaCl solution was added to
each tube and incubated for 2 h at 20 8C. After centrifugation at
8117  g for 5 min at 4 8C, DNA contained in the supernatant
fraction was precipitated by addition of 2 volumes of ice cold
isopropyl alcohol. The solution was kept at 20 8C for 24 h. After
a new centrifugation at 8117  g for 5 min at 4 8C, the
supernatant was discarded and the tubes were left open
overnight at RT to allow the alcohol to evaporate. Subsequently,
50 ml of sterile distilled water was added to each tube and left in
a water bath for 1 h at 37 8C. The DNA samples were stored at
20 8C until further analysis.
DNA primers S13 (50-CTCCACCTGGACCGGCGAT-30) and S62
(50-GACTAGCCTGCCAAGTCG-30) were selected based on the
nucleotide sequence of the 531-bp fragment (proline-rich
region) of a speciﬁc gene that encodes the 36-kDa antigen of
M. leprae.21
The PCR technique was performed by adding 5.2 ml sterile
water, 2 ml Tween 20, 10 ml Master Mix (Promega, USA), 0.4 ml
primers, and 2 ml DNA template to each microtube. Subsequently,
the samples were subjected to 38 ampliﬁcation cycles after an
initial denaturation step at 94 8C for 5 min. An ampliﬁcation cycle
consisted of 1 min at 94 8C, 2 min at 56.5 8C, and 2 min at 72 8C. A
Table 1
Frequency of positive serum and salivary anti-PGL1 antibody titers and nasal M. leprae DNA among leprosy household contacts
Leprosy contacts—clinical form of the index case Anti-PGL1 antibodies M. leprae DNA
Serum IgG, n (%) Serum IgM, n (%) Saliva IgA, n (%) Saliva IgM, n (%) Nasal, n (%)
Paucibacillary (n = 50) 8 (16%) 26 (52%) 11 (22%) 5 (10%) 3 (6%)
Multibacillary (n = 85) 6 (7.1%) 54 (63.5%) 30 (35.2%) 9 (10.5%) 9 (10.6%)
Fisher’s test p-value >0.1 >0.1 >0.1 1.0 >0.5
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Four microliters of the amplicon were subjected to electrophoresis
in a 2% agarose gel. The DNA was visualized under ultraviolet light
after staining the gel with ethidium bromide.
2.6. Acid-fast stain of nasal smears
Nasal smears were collected, spread on a slide, heat-ﬁxed, and
stained by Ziehl–Neelsen method.
2.7. Statistical analysis
The data were analyzed using non-parametric tests as the
data did not follow a Gaussian distribution (Kolmogorov–
Smirnov test, p < 0.0001). The Wilcoxon and Spearman tests
were used to compare the antibody isotype titers between
paired groups. The Mann–Whitney test was used to compare
the isotype antibody titers between unpaired groups. Fisher’s
test was used to calculate the probability of association
between the clinical form of the leprosy disease and the
frequency of positive or negative antibody/molecular results;
also for comparing serum and salivary antibody parameters.
The software used for the statistical analysis was Prism
GraphPad Instat version 3.10. The level of statistical signiﬁ-
cance was considered to be 0.05.Serum anti-PGL1 IgG
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Figure 1. Correlation of serum IgG/IgM and salivary IgA/IgM against PGL1 betw3. Results
3.1. Serological and molecular data in household leprosy (HHL)
contacts
Table 1 presents the positivity of serological and molecular
parameters in HHL contacts. Serum anti-PGL1 IgG and IgM were
positive in 14 (10.4%) and 80 (59.3%) out of 135 samples,
respectively. Salivary anti-PGL1 IgA and IgM titers were positive
in 41 (30.3%) and 14 (10.4%) out of 135 samples, respectively.
Twelve out of 135 samples (26.7%) were positive for M. leprae DNA.
No statistical signiﬁcance was found when the frequencies of
positive serum and salivary antibodies or the M. leprae DNA were
associated with the PB and MB HHL contacts.
3.2. Correlation between HHL contacts and index cases
Figure 1 demonstrates the correlation of serum and salivary
antibody titers between HHL contacts and index cases (n = 97).
Salivary anti-PGL1 IgA titers showed good correlation comparing
HHL contacts and index cases (r = 0.25, p < 0.01); a similar
observation was made for salivary anti-PGL1 IgM (r = 0.34,
p = 0.005) and serum anti-PGL1 IgG levels (r = 0.39, p < 0.0001).
The same was not observed for serum anti-PGL1 IgM (r = 0.14,
p > 0.05).salivary anti-PGL1 IgM
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Figure 3. Serum anti-PGL1 IgM and IgG titers in IgG-positive and IgG-negative
samples. The dashed line indicates the cut-off value.
Table 2
Frequency of positive and negative serum and salivary anti-PGL1 antibody titers in
leprosy household contacts
Serum IgG and/or IgM antibodies
Salivary IgA and/or
antibodies
Positive, n (%) Negative, n (%) Total, n (%)
Positive 21 (46.7%) 24 (53.3%) 45 (100%)
Negative 64 (71.1%) 26 (28.9%) 90 (100%)
Fisher’s test p < 0.01
P.B. Cabral et al. / International Journal of Infectious Diseases 17 (2013) e1005–e1010e10083.3. Controls (CT group)
Salivary IgA/IgM and serum IgG antibody titers from the CT
group were below the cut-off values (Figure 2a and 2b,
respectively). Two serum samples showed IgM antibody titers
above 2.0 (Figure 2b). Levels of salivary anti-PGL1 IgA were much
lower than those of the other groups (p < 0.0001). In respect to
salivary IgM, titers were lower than those of the HHL contact
group; however, a statistical difference was only found when their
levels were compared to those of the patients (p = 0.02). In regard
to serum antibodies, levels of the IgG isotype did not differ from
those of the contacts, and were much lower than those of the
patients (p < 0.05). Serum anti-PGL1 IgM levels were much lower
than those of the HHL contacts (p = 0.01) and the patients
(p = 0.0009).
3.4. Serum antibody isotypes in HHL contacts
A statistically signiﬁcant correlation was found between
serum IgM and IgG isotypes for both the MB (r = 0.39,
p < 0.0001) and the PB (r = 0.39, p < 0.005) HHL contacts.However, the serum IgM and IgG levels were very different from
one another (p < 0.0001). Considering serum IgG-negative and
IgG-positive samples separately (Figure 3), a high frequency of
anti-PGL1 IgM positivity (71 out of 121 samples; 58.6%) was found
in IgG-negative samples (p < 0.0001). For IgG-positive samples,
IgM antibodies were also positive in most of the samples (10 out of
14 samples; 71.4%) and their levels did not differ signiﬁcantly
from the IgG titers (p > 0.1).
3.5. Salivary antibody isotypes in HHL contacts
A statistically signiﬁcant positive correlation between salivary
IgA and IgM was found in both PB (r = 0.54, p < 0.0001) and MB
(r = 0.61; p < 0.0001) HHL contacts. Twenty-four out of 45 HHL
contacts who demonstrated positivity for salivary antibodies
(53.3%) were negative for serum antibodies. Conversely, 64 out of
90 HHL contacts who demonstrated negativity for salivary
antibodies (71.1%) were positive for serum antibodies (Table 2,
p < 0.01).
3.6. Direct and molecular detection
No HHL contacts presented direct nasal smear detection. M.
leprae DNA was found in the nasal swabs of nine out of the 85
MB HHL contacts (10.6%) and in three out of the 50 PB HHL
contacts (6.0%). Among the 12 contacts who were positive for
M. leprae DNA (Table 3), ﬁve were positive for serum anti-PGL1
IgM, seven were positive for salivary anti-PGL1 antibodies, and
one was positive for all of the isotypes, except for salivary anti-
PGL1 IgM. This individual was the only one who did not have a
BCG scar.
Table 3
Serum and salivary anti-PGL1 titers in multibacillary (MB) and paucibacillary (PB) leprosy household contacts whose nasal swabs were PCR-positive for M. leprae DNA. The
presence or absence of the BCG scar was also observed. Cut-off values were 1.3 and 0.5 for serum and salivary antibodies, respectively.
Leprosy household contact Clinical form of index case Age (years) BCG scar Serum Saliva
IgG IgM IgA IgM
C49.3 MB 19 Yes 0.7 3.1 0.64 0.01
C13.1 MB 73 Yes 0.1 0.4 0.14 0.05
C13.2 MB 55 Yes 0.3 0.7 0.58 0.02
C32.1 MB 26 Yes 0.6 2.2 0.18 0.03
C1.3 MB 27 Yes 0.3 0.4 0.50 0.02
C1.6 MB 52 Yes 0.3 0.8 1.70 3.00
C9.4 MB 30 Yes 1.1 1.1 1.10 0.03
C8.4 MB 29 Yes 0.3 0.6 0.60 0.04
C53.1 MB 34 Yes 0.8 1.7 0.08 0.00
C46.2 PB 13 Yes 0.9 3.1 0.10 0.02
C12.4 PB 20 Yes 0.3 1.0 0.13 0.05
C6.1 PB 39 No 1.4 2.1 1.10 0.14
BCG, bacille Calmette–Gue´rin.
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Early detection of the disease is a strategy to interrupt M. leprae
transmission and to prevent the occurrence of physical disabilities,
a severe consequence of late diagnosis.1 In endemic areas, sensitive
and speciﬁc serological tests associated with molecular param-
eters could be of great use for following contacts at high risk of
developing the disease.11
When a clinical examination of a leprosy contact is performed,
suspected cases can be registered. Bazan-Furini et al.9 detected
new leprosy cases in 3.3% of patient contacts (co-prevalent cases).
Similar results have been found by others,4,28 who observed a rate
of co-prevalent cases of 5.2%. In our study, we did not ﬁnd any co-
prevalent case among the contacts.
Many authors refer to anti-PGL1 IgM as the main serological
parameter in leprosy.10,29–31 It is known that the rheumatoid factor
is one of the main causes of false-positive values in IgM detection.
The false-positivity occurs in toxoplasmosis32 and other dis-
eases.33,34 Serum anti-PGL1 IgG could be an important parameter
for evaluation because only a few contacts present it. In the present
study, 58% of the IgG-negative samples showed positive IgM. On
the other hand, 71.4% of the IgG-positive samples were also
positive for IgM. Moreover, among 17 volunteers living in a low
endemic city, who reported no contact with leprosy patients, none
presented seropositivity for IgG; however, two of them showed
anti-PGL1 IgM titers above 2.0. This means that both isotypes
should always be measured. We believe that those individuals that
are positive for both of the isotypes should be followed every year.
Additionally, those who present with anti-PGL1 IgM levels with
titers above 3.0 (regardless of IgG) should be followed as well. We
are doubtful about the usefulness of immunochromatography tests
for this purpose, since they are not able to quantify antibodies in
samples.
The percentage of leprosy contacts with positive titers of
salivary anti-PGL1 IgA antibodies was 32.5%, much lower than the
frequency reported by Smith et al. (68%).13
We found that 24 out of 45 HHL contacts (53.3%) who were
positive for salivary IgA and/or IgM antibodies did not present
serum antibodies. Assuming a diagnostic speciﬁcity of approxi-
mately 91% for the salivary anti-PGL1 antibody test,17 we can
hypothesize that 48% of the individuals were infected but did not
develop serum antibodies. This probably means that they are
infected with M. leprae but that they will not necessarily acquire
the disease. Conversely, 64 out of 90 HHL contacts (71.1%) who
were negative for salivary anti-PGL1 antibodies presented serum
IgG and/or IgM antibodies. It is already known that the
maintenance of long-term immunological memory in the mucosal
surfaces is a great challenge.35 After mucosal colonization, thebacteria can translocate into the systemic circulation, reducing the
bacterial load in the nasal surfaces. In this case, it is reasonable to
assume that secretory antibodies will decrease, meanwhile serum
antibody levels will increase.
M. leprae DNA was found in 8.9% of the nasal samples. Other
authors have found percentages of positivity varying from 1.6% to
19.35%.10,12,13,36,37
One person showed both positive molecular and serological
parameters, except for salivary anti-PGL1 IgM, and did not show a
BCG scar. According to Lobato et al.,11 individuals without a BCG
scar are at a higher risk of developing leprosy. We believe that this
person should be followed up.
We strongly suggest that serum anti-PGL1 IgG/IgM and salivary
anti-PGL1 IgA/IgM measurements should be used to follow leprosy
household contacts. The detection of nasal M. leprae DNA is not
essential to follow leprosy contacts because of the high percentage
of negative results in the contacts, even those with positive
serology.
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